MD Anderson and Allogene Therapeutics announce strategic collaboration to accelerate advancement of allogeneic CAR T therapy (AlloCAR T)
Clinical and translational research collaboration will evaluate multiple AlloCAR T candidates across the Allogene portfolio targeting multiple tumor types
MD Anderson News Release October 15, 2020
and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene¡¯s broad portfolio of hematologic and solid tumors.
¡°MD Anderson¡¯s expertise in innovative clinical trials and well established translational research infrastructure will provide unique insights that will help expedite the development of AlloCAR T therapies,¡± said Rafael Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer of Allogene. ¡°Coupled with Allogene¡¯s cell therapy expertise, we believe this institution-industry alliance could play an important role in bringing this next revolution in oncology treatment to patients.¡±
Under the agreement, MD Anderson and Allogene will collaborate on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. Allogene will provide funding, developmental candidates, and other support. Responsibility for regulatory filings will be agreed upon by the joint steering committee.
¡°We share Allogene¡¯s commitment to advancing novel therapies that will translate into effective treatments for cancer patients,¡± said , ad interim division head of Cancer Medicine and chair of Lymphoma and Myeloma at MD Anderson. ¡°This collaboration will enable us to work together closely to advance allogeneic cell therapies to better address significant unmet medical needs for patients across the spectrum of oncologic diseases.¡±